Nuvectis Pharma, Inc.·4

May 9, 6:53 PM ET

Mosseri Marlio Charles 4

4 · Nuvectis Pharma, Inc. · Filed May 9, 2025

Insider Transaction Report

Form 4
Period: 2025-05-06
Transactions
  • Purchase

    Common Stock

    2025-05-08$8.65/sh+100$8652,909,032 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-06$8.40/sh+2,340$19,6562,886,461 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-06$8.64/sh+10,104$87,2992,896,565 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-08$8.65/sh+50$4332,908,932 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-07$8.40/sh+2,703$22,7052,899,268 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-07$8.64/sh+9,614$83,0652,908,882 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-08$8.65/sh+100$8652,909,132 total(indirect: By Emerald Hill Ventures SARL SPF.)
  • Purchase

    Common Stock

    2025-05-08$8.65/sh+2,400$20,7602,911,532 total(indirect: By Emerald Hill Ventures SARL SPF.)
Footnotes (1)
  • [F1]Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.

Documents

1 file
  • 4
    tm2514669-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT